David Sallman, MD | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

David Sallman, MD

  1. Home
Position / Title: 
Institution: 
H. Lee Moffitt Cancer Center & Research Institute
Online Profile: 
https://moffitt.org/providers/david-sallman/
Primary Disease Area of Focus: 
  • Acute Myeloid Leukemia (AML)
  • Aplastic Anemia
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPN)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Dr. David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and II clinical trials) for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), based on the underlying mutational drivers of each disease.

Practice Location: 
H. Lee Moffitt Cancer Center & Research Institute
Tampa , FL ,
US
Physician Status: 
  • accepting new patients

Other pages on our site that mention David Sallman:

  1. Research Article - The Problem of TP53-Mutant MDS/AML
  2. Research Article - To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia
  3. Research Article - TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
  4. Research Article - Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
  5. Research Article - Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
  6. Research Article - Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)
  7. Webinar - Ninth International Bone Marrow Failure Disease Scientific Symposium